Concepedia

Camelia Gliser

CG

Statistics

Publications

20

Citations

4K

H-Index

19

Active since

2013

Affiliations

Agios Pharmaceuticals (United States)(Current)

Memorial Sloan Kettering Cancer Center

Massachusetts General Hospital

Harvard University

Cornell University

Camelia Gliser is an author at Agios Pharmaceuticals (United States) specializing in cancer research, medicine, and pathology.

Top concepts

Publications per year

2013–2021

20

Publications

20

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

Ghassan K. Abou‐Alfa, Teresa Macarulla, Milind Javle et al. · The Lancet Oncology · 2020 · 995 citations · Full text

, , +8

Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation

Fang Wang, Jeremy Travins, Byron DeLaBarre et al. · Science · 2013 · 789 citations

Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer

Supriya K. Saha, Christine A. Parachoniak, Krishna S. Ghanta et al. · Nature · 2014 · 455 citations · Full text

, , +11

Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With <i>IDH1</i> Mutation

Andrew X. Zhu, Teresa Macarulla, Milind Javle et al. · JAMA Oncology · 2021 · 436 citations · Full text

Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study

Maeve A. Lowery, Howard A. Burris, Filip Jankú et al. · ˜The œLancet. Gastroenterology & hepatology · 2019 · 215 citations · Full text

, , +8

1–5 of 20